800-845-6913
Tuteur & Associates, LLC | Knowledge is Power.
December 15, 2006
West Haven, Connecticut – Bayer HealthCare Pharmaceuticals All rights reserved. , in collaboration with the FDA, is informing health care professionals of important safety revisions to the U.S. product information for Trasylol® (aprotinin injection) following an FDA Advisory Committee meeting earlier this year. These safety revisions relate primarily to renal function and hypersensitivity. Continue reading, ‘12-15-2006 | Bayer Pharmaceuticals Trasylol® (aprotinin injection) Press Release.’